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ABSTRACT
Arterial hypertension is a highly prevalent disease and is 
associated with increased cardiovascular risk. Despite great 
advances in drug therapy, a considerable number of patients 
do not have an effective control of the disease, despite the use 
of multiple drugs, usually in high doses. Renal sympathetic 
denervation (RSD) has proved to be a promising therapy, with 
high safety and efficacy in preliminary studies in patients with 
resistant hypertension. The role of the sympathetic nervous 
system in the physiopathology of hypertension is well known, 
and is the rationale for the ablation of sympathetic fibers by 
transluminal delivery of radiofrequency in the renal arteries. 
In the last few years, results from case series, non-controlled 
studies and one multicenter randomized trial with a limited 
number of patients have shown a significant decrease in short 
and mid-term blood pressure levels. The objective of this re-
view was to gather evidence on the use of RSD in the control 
of resistant hypertension and describe technical aspects and 
perspectives of the procedure.
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RESUMO
Denervação Simpática Renal Percutânea
A hipertensão arterial sistêmica (HAS) é uma doença de alta 
prevalência e está comprovadamente relacionada a maior 
risco de eventos cardiovasculares. Apesar dos grandes avanços 
no tratamento farmacológico, uma parcela considerável dos 
pacientes não obtém um controle efetivo da doença, a des-
peito do uso de múltiplos fármacos e em doses elevadas. A 
denervação simpática renal percutânea (DSRP) tem se mostrado 
uma terapia promissora, com elevada segurança e eficácia 
em estudos preliminares em pacientes com HAS resistente. O 
papel do sistema nervoso simpático na fisiopatologia da HAS 
é bem conhecido e constitui o racional para a ablação das 
fibras simpáticas, por meio da aplicação de radiofrequência 
por via transluminal nas artérias renais. Nos últimos anos, 
resultados provenientes de algumas séries de casos, estudos 
não controlados e um estudo randomizado multicêntrico, com 
número limitado de pacientes, mostraram queda significativa 
dos níveis tensionais em curto e médio prazos. Esta revisão 
teve por objetivo reunir as evidências do uso da DSRP no 
controle da HAS resistente de maneira crítica, assim como 
descrever aspectos técnicos do procedimento e perspectivas.
DESCRITORES: Hipertensão. Resistência a medicamentos. 
Rim. Revisão.
S ystemic arterial hypertension (SAH) is an endemic disease in Brazil and worldwide, and is considered the main modifiable risk factor in cardiovascular 
disease prevention. Population studies conducted in 
Brazilian cities over the last two decades have shown 
a SAH prevalence > 30%, expected to increase due 
to an aging population.1 The treatment of SAH has 
proven to reduce the risk of developing cardiovascular 
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disease and, despite the advancements in knowledge 
and therapeutic arsenal, it remains a disease with low 
control rates.2
The causes of inadequate hypertension control are 
numerous, such as poor adherence to lifestyle changes 
and drug treatment, blood pressure (BP) measurement 
errors, white-coat hypertension, medications that develop 
or aggravate hypertension, and undiagnosed secondary 
causes of hypertension. Even after considering these 
possible causes, a percentage of patients still have 
difficulties in controlling BP, despite the use of mul-
tiple medications. This condition is known as resistant 
hypertension (RH).
RH is defined as the condition in which BP re-
mains above target (≥ 140/90 mmHg) despite the use 
of three or more different classes of antihypertensive 
drugs, including a diuretic, at optimal doses.3 Recent 
epidemiological data have defined the prevalence of 
RH as approximately 15% of cases of SAH.3 BP con-
trol in these patients is a major challenge, requiring 
the combination of multiple antihypertensive drugs, 
but still not achieving adequate control. Considering 
this challenge, new interventional therapeutic options 
have been studied; among them, percutaneous renal 
sympathetic denervation (RSD) has gained promi-
nence after demonstrating significant BP reduction 
in RH cases.4
ROLE OF THE KIDNEY AND SYMPATHETIC 
NERVOUS SYSTEM IN THE PHYSIOPATHOLOGY 
OF HYPERTENSION
The renal sympathetic nervous system (SNS) com-
prises a dense network of post-ganglionic efferent fibers 
originating in the hypothalamus that reach the kidneys, 
through the pre- and paraspinal ganglia (T10-T12). 
Afferent fibers emerge from the renal pelvis and ascend 
to the autonomic center in the brain, and to the contra-
lateral kidney through the roots of the ipsilateral dorsal 
ganglia (T6-L4), allowing a cross-regulation between 
the kidneys and the SNS. Both afferent and efferent 
fibers travel the path of the renal arteries through the 
adventitial layer of the vessel.5
The renal SNS plays a vital role in the onset and 
perpetuation of primary SAH, especially in the non-
elderly population, as it contributes significantly to the 
increase in cardiac output and vascular tone. There is 
evidence suggesting the involvement of the SNS in this 
population, by demonstration of elevated plasma and 
urinary norepinephrine levels, and the increased activity 
of post-ganglionic sympathetic neurons and peripheral 
alpha-adrenergic receptors.6 Sympathetic hyperacti vity 
has also been demonstrated in patients with SAH related 
to sleep apnea, obesity, diabetes mellitus, and chronic 
renal failure.7-9
Experimental studies have demonstrated higher renal 
sympathetic activity in patients with primary hypertension, 
confirmed by measurement of norepinephrine released 
into plasma by the renal sympathetic nerves.10 
The efferent sympathetic activity, for the kidneys, 
causes renin release, with subsequent activation of 
the renin-angiotensin-aldosterone system, leading to 
BP increase, increased tubular sodium retention, and 
reduction in renal blood flow.11,12 
Afferent signaling from the kidneys to the SNS, 
which is stimulated by reduced renal flow, causes an 
increase in efferent sympathetic activation to the kid-
neys, vessels, and heart, perpetuating the process.13,14 
The rationale of percutaneous RSD therapy is to block 
this pathway, reducing the role of the SNS in SAH.
RSD FOR CONTROL OF RESISTANT SAH
Denervation of the SNS has been used as anti-
hypertensive therapy for over 50 years, through the 
non-selective thoracolumbar splanchnincectomy. This 
procedure was able to control SAH and to improve the 
clinical condition of a significant number of patients, 
especially in cases of malignant hypertension, whose 
mortality rate at the time was greater than 50% at five 
years.15 However, the procedures had many undesirable 
side effects and, later, with the emergence of effective 
and safe antihypertensive medications, and due to the 
complexity and morbidity of the surgical sympathetic 
denervation procedure, this treatment modality was 
abandoned.
Based on the aforementioned physiopathological 
mechanisms and the evolution of interventional medicine, 
percutaneous RSD, through transluminal radiofrequency 
ablation of renal sympathetic fibers, has recently been 
the focus of attention in the treatment of RH. One of 
the first prospective studies showed an average reduc-
tion in BP of 27 mmHg for systolic and 17 mmHg for 
diastolic pressure at 12 months in patients with RH, 
and no major complications have been reported.16,17
PERCUTANEOUS RSD TECHNIQUE
The Symplicity® renal denervation system (Medtronic 
– Santa Rosa, United States) is the pioneer device in 
RSD and at present, it is the system that has been 
most often tested in clinical trials (Figure 1). Before 
staring the procedure, unfractionated heparin must be 
administered to maintain activated clotting time (ACT) 
> 250 seconds. The technique consists of inserting 
a guide catheter through femoral access compatible 
with a 6F sheath, followed by the introduction of a 
catheter with radiofrequency energy emission, which 
is used four to six times, two minutes each time, us-
ing a spiral-shaped application, from the most distal 
segment toward the ostium of each renal artery. The 
catheter tip must be in contact with the artery wall to 
cause a thermal injury, which is predominantly restricted 
to the sympathetic fibers located in the adventitia, as 
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they are more sensitive to heat than the surrounding 
tissues. The impedance of the catheter tip in contact 
with the artery is measured in real time, so that when 
the tissue temperature rises during each application, 
there is the reduction in the system impedance. An 
absolute reduction of 10% or more in the impedance 
is a marker of successful ablation.5
The procedure can be performed while the patient 
is awake; however, in most cases, systemic analgesia 
and conscious sedation are required, due to intense 
back pain during radiofrequency application; it may 
even require deeper sedation with airway protection. 
Edema and spasm of the arterial wall may occur as a 
result of thermal injury, shown as parietal irregulari-
ties on angiography (Figure 2) without hemodynamic 
involvement, and spontaneous resolution after the 
procedure is the usual outcome.18 Immediate reversal 
can be attempted with intra-arterial vasodilators, such 
as nitroglycerin and verapamil. The use of the radial 
approach has been reported with success.19
The Symplicity HTN-2 study is the only random-
ized controlled trial published to date, and represents 
the greatest clinical evidence for percutaneous RSD use 
in patients with resistant primary SAH.4 It was a multi-
center study (24 centers in Europe, Australia, and New 
Zealand), in which 106 adult patients were randomized 
(aged 18 to 85 years) with essential hypertension and 
systolic BP > 160 mmHg (or > 150 mmHg in diabet-
ics), measured in the office, and in regular use of at 
least three classes of antihypertensive drugs. Individuals 
with previous renal intervention, those with unfavorable 
kidney anatomy (luminal diameter < 4 mm, length of 
renal artery < 20 mm, or significant renal anomalies), 
type 1 diabetes, renal failure with glomerular filtra-
tion rate < 45 mL/min, severe valvular stenosis and 
acute myocardial infarction, unstable angina, or stroke 
within the last six months were excluded. These sub-
jects were randomized to percutaneous RSD and to a 
control group with medication only, with the primary 
endpoint of BP reduction at six months. At the end of 
the study, the intervention group showed a significant 
decrease in BP measured in the office when compared 
to the control group (–33/–11 mmHg, P < 0.0005). The 
percutaneous RSD resulted in a reduction ≥ 10 mmHg 
and ≥ 20 mmHg of systolic BP in 75% and 63% of 
patients, respectively.
At the 12-month follow-up, patients in the inter-
vention group maintained a substantial reduction in BP 
without further complications and without associated 
worsening of renal function.20 Of the 51 patients in the 
control group, after the initial six months, there was 
a crossover to percutaneous RSD in 31 of them, who 
also showed a significant reduction in BP. Recently, the 
three-year results of the HTN-1 study were presented, the 
longest clinical follow-up to date, showing maintenance 
of BP reduction results in the three-year evolution.21
Regarding the safety profile of the procedure, in 
the Simplicity HTN-2 study, the complications related 
to percutaneous RSD were rare. There was one case 
of pseudoaneurysm of the femoral artery; one case of 
significant decrease in BP after the procedure, requir-
ing reduction of antihypertensive drugs and prolonged 
hospitalization for observation of lower-limb paresthesia; 
and one case of persistent low back pain requiring 
analgesia, which improved after 1 month.
During the procedure, seven patients had brady-
cardia. One of the concerns of the study regarded the 
possible worsening in renal function caused by hemo-
dynamic changes and renal autoregulation. However, 
there was no difference between the groups regarding 
glomerular filtration rate and levels of cystatin C. The 
implementation of percutaneous RSD therapy in patients 
with more advanced stage of chronic renal failure was 
Figure 1 – Symplicity® Renal Denervation System.
Figure 2 – Arterial spasm and edema after sympathetic denervation.
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tested in a pilot study,22 in which 15 patients with a 
mean glomerular filtration rate of 31 mL/min and RH 
were assessed. After a 12-month follow-up, there were 
significant reductions in BP without impaired renal 
function. 
With the results reported by the Simplicity HTN-1 
(Phases 1 and 2) and Simplicity HTN-2 (Phase 3) stu-
dies in 2010, the Symplicity® device for percutaneous 
RSD received approval for its clinical use in Europe 
(CE marking). Currently, four other devices have been 
approved in Europe, namely: the EnligHTN® renal de-
nervation system, by St. Jude Medical (St. Paul, United 
States); the Vessixs V2® renal denervation system, by 
Boston Scientific Corporation (Natick, United States); 
the OneShot® system, by Covidien (Mansfield, United 
States); and the Paradise® system, by ReCor Medical 
(Menlo Park, United States). In Brazil, only the Sim-
plicity catheter has been approved by the Brazilian 
National Health Surveillance Agency (Agência Nacional 
de Vigilância Sanitária – ANVISA), but its generator is 
still awaiting approval. None of the systems have been 
approved by the Food and Drug Administration (FDA) 
to date, and the Simplicity HTN-3 study is forthcoming, 
which included a placebo procedure for comparison.
The use of radiofrequency catheters with irrigated 
tip, designed for ablation of cardiac arrhythmia, has 
been tested as an alternative to the catheters specifi-
cally used for percutaneous RSD, with positive results 
in preliminary studies.23,24
INDICATION OF PERCUTANEOUS RSD
The treatment of RH through percutaneous RSD 
has been an attractive alternative to exclusive drug 
therapy. Despite the positive and promising results of 
the Simplicity studies and its approval in Europe, some 
considerations should be made before its clinical in-
dication. As mentioned above, to date there has been 
only one randomized, controlled trial, whose primary 
endpoint did not include clinical events, the number of 
patients was not significant, the control group was not 
submitted to any additional treatment, and the study 
was not double-blind. Moreover, there is no long-term 
follow-up to ensure efficacy and safety of this therapy 
over an extended period. It is possible that, over time, 
there is a regeneration of renal sympathetic fibers,25 a 
fact already described in renal transplant grafts, reduc-
ing the long-term effects of percutaneous RSD. With the 
increasing number of cases, new complications not yet 
observed in earlier studies may arise. There have been 
reports of renal artery stenosis post-RSD,26 possibly 
caused by vascular injury in the renal artery submit-
ted to radiofrequency thermal injury, with consequent 
scarring and luminal narrowing of the vessel.
Not all patients undergoing percutaneous RSD 
show a significant reduction in BP. Further studies are 
necessary to identify markers of good response to the 
procedure and to avoid exposure of individuals who 
will not benefit from an invasive procedure. 
In the Simplicity HTN-2 study, it was observed 
that BP reduction in the intervention group was less 
significant in 24-hour ambulatory blood pressure moni-
toring (ABPM) than in the measurements made during 
medical consultations. This is another issue that needs 
to be clarified.
Much has been debated about the definition of RH 
and, despite the difficulty to control the disease, in most 
cases BP levels can be reduced with a combination of 
four or more drugs. Some studies have shown significant 
BP reduction in cases of RH with the association of 
spironolactone.27,28 However, increasing the number of 
prescribed drugs brings a higher risk of adverse events 
and hinders drug therapy adherence – a major cause of 
hypertension treatment failure. Thus, the percutaneous 
RSD may possibly be considered an option for cases 
where there is difficulty in adherence to therapy with 
multiple drugs. 
Considering these facts, the European Society of Hy-
pertension published a position regarding the appropriate 
indication of percutaneous RSD (Table 1).29
FOLLOW-UP AFTER PERCUTANEOUS RSD
There is no consensus regarding the care of patients 
undergoing percutaneous RSD. The use of dual antiplatelet 
therapy with acetylsalicylic acid and clopidogrel for a 
short period may be beneficial in reducing thrombotic 
events.30 Initially, the patient should be assessed monthly 
for BP revaluations and antihypertensive medication 
adjustment. Routine assessment with renal artery imaging 
to identify possible complications, especially stenosis, 
remains controversial. It appears reasonable to perform 
a Doppler ultrasound of the renal arteries within six 
months.17 Other methods, such as magnetic resonance 
angiography and computed tomography angiography, 
are alternatives.
PERSPECTIVES
The future of percutaneous RSD looks promising 
for the treatment of both the most resistant forms of 
hypertension and some specific clinical situations. 
New therapeutic options are always welcome against a 
disease with high prevalence and impact on the popu-
lation, such as SAH. New cryoablation techniques for 
renal denervation induced by ultrasound, use of local 
neurotoxic drugs, and new radiofrequency denervation 
catheters are being developed and researched.31 Recently, 
a study on safety and efficacy has been published with 
positive results of the radiofrequency catheter with mul-
tiple electrodes (EnligHTN® renal denervation system, 
Figure 3), which are geometrically positioned to reduce 
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the need for catheter manipulation inside the renal 
artery and, consequently, the risk of complications.32 
With technology improvement, based on results of new 
studies, there is a trend of increase in the efficiency 
and safety of the procedure, expanding its indication.
As the sympathetic system has direct involvement 
in the physiopathology of other diseases, new possibili-
ties for percutaneous RSD use have emerged. Improved 
glycemic control and reduced insulin resistance have 
been demonstrated in individuals with impaired glu-
cose metabolism submitted to percutaneous RSD.33 
The use of RSD in patients with heart failure, cardiac 
arrhythmias, and sleep apnea has also been the object 
of investigations.34-37
CONCLUSIONS
Percutaneous RSD is a new invasive therapeutic 
modality, whose results demonstrated initial significant 
reduction in blood pressure in patients with resistant 
hypertension. The procedure has been shown to be 
safe and of low complexity. Despite these promising 
results, this is a new therapy, with limited long-term 
follow-up and whose clinical evidence is still scarce; 
therefore, its indication must be made with caution. 
In addition to the treatment of resistant hypertension, 
other diseases may benefit from percutaneous renal 
sympathetic denervation therapy, such as heart failure, 
arrhythmia, sleep apnea, and metabolic diseases. Cur-
rently, there are several ongoing lines of research and 
studies in these areas. 
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TABLE 1  
Recommendations for the indication of percutaneous renal sympathetic denervation (RSD)  
in resistant hypertension (RH)
First step Confirm RH and rule out the following 
situations:
Pseudoresistant hypertension with ambulatory 
blood pressure monitoring and home blood 
pressure monitoring. 
Secondary hypertension.
Causes that maintain high blood pressure and 
can be corrected, such as sleep apnea, severe 
obesity, use of medications that increase blood 
pressure, and high salt intake.
Second step Optimize antihypertensive therapy with at 
least three classes of drugs, with one diuretic, 
at maximum tolerated doses. Consider the 
association of aldosterone antagonists (with 
renal function and hyperkalemia monitoring) 
and evaluate the response with ambulatory 
blood pressure monitoring.
Third step Assess contraindications of the procedure: Solitary kidney, renal artery with a diameter 
< 4.0 mm and length < 20 mm, multiple 
renal arteries, significant stenosis, previous 
interventions such as renal artery 
angioplasty, estimated glomerular filtration rate 
< 45 mL/min/1.73m2.
General 
recommendations 
Perform the procedure in centers of excellence 
in the treatment of hypertension. 
Use devices that have demonstrated efficacy 
and safety in clinical trials.
Figure 3 – EnligHTN® Renal Denervation System.
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